News &amp; Updates

Women with central adiposity, regardless of menopausal status, are at risk of developing breast cancer, according to a study.

Central obesity bears risk of breast cancer

Older hepatocellular carcinoma patients less knowledgeable about survivorship issues

Older patients with hepatocellular carcinoma (HCC) appear to know less about survivorship issues, according to a study involving a population of 110 ethnically diverse HC survivors.

Older hepatocellular carcinoma patients less knowledgeable about survivorship issues

ALL treatment: Current settings, future goals

Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.

ALL treatment: Current settings, future goals

Tailored follow-up does little to promote treatment adherence among elderly cancer patients

A tailored follow-up programme for frail and vulnerable elderly cancer patients does not appear to particularly improve the comprehensive geriatric assessment in promoting treatment adherence, a recent study has found.

Tailored follow-up does little to promote treatment adherence among elderly cancer patients

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

Men on androgen deprivation therapy at risk of dementia, Alzheimer’s disease

Androgen deprivation therapy (ADT) in men with prostate cancer increases the risk of dementia and Alzheimer’s disease, reveals a recent study. Such risk further increases when said treatment is given for more than 12 months.

Men on androgen deprivation therapy at risk of dementia, Alzheimer’s disease

CC-486 maintenance preserves survival benefit, QoL in older AML patients

In older patients with acute myeloid leukaemia (AML), CC-486 maintenance therapy after intensive chemotherapy (CT) with or without consolidation CT led to improved survival regardless of MRD* status, and preserved baseline QoL status, according to the QUAZAR AML-001 trial presented at ASH 2020.

CC-486 maintenance preserves survival benefit, QoL in older AML patients